Overview
SIST EN ISO 5840-3:2021/A1:2025 is an important European and international standard that specifies requirements for cardiovascular implants, particularly cardiac valve prostheses designed for implantation using transcatheter techniques. This Amendment 1 updates the original EN ISO 5840-3:2021 and reflects the latest consensus and technical advancements related to heart valve substitutes, covering newly developed and modified products, their delivery systems, packaging, labelling, and performance evaluation.
Developed collaboratively by CEN (European Committee for Standardization) and ISO, this standard provides harmonized guidelines essential for medical device manufacturers, healthcare professionals, and regulatory authorities involved with transcatheter heart valve implants. It ensures the safety, quality, and performance of products in this rapidly evolving sector.
Key Topics
The standard amendment addresses several critical areas related to transcatheter heart valve substitutes:
- Applicability: Covers both new and modified transcatheter heart valve devices, including their delivery systems and accessory components.
- Performance Criteria: Establishes key performance requirements, such as:
- Safe, accurate loading and deployment of the valve on the delivery system
- Retrieval and repositioning capabilities (if applicable)
- Long-term structural and functional integrity of the device
- Compatibility and interaction with cardiac anatomical structures and other implants
- Maintenance of forward blood flow with minimal pressure difference
- Effective prevention of backward flow and minimization of leakage
- Resistance to device migration, embolization, hemolysis, and thrombus formation
- Device biocompatibility and sterility
- Reproducibility of functional results
- Testing Methods: Provides clear measurement requirements for pressure and flow, ensuring the precision and reliability of in vitro testing.
- Adverse Events Reporting: Aligns reporting of adverse device effects (ADE) with ISO 14155, distinguishing between serious and non-serious events for clinical risk management.
Applications
The scope of SIST EN ISO 5840-3:2021/A1:2025 covers practical, clinical, and regulatory applications, including:
- Manufacturing & Design: Assists manufacturers in developing and validating transcatheter heart valve prostheses and associated delivery devices to meet recognized international benchmarks.
- Quality Assurance: Facilitates robust quality control, packaging, and labelling processes to ensure product safety and traceability.
- Clinical Evaluation: Supports clinicians and regulatory authorities in assessing device safety, functionality, and performance during pre-clinical and clinical stages.
- Compliance & Approval: Provides a foundation for regulatory submissions, conformity assessment, and CE marking processes in the European and global medical device markets.
Related Standards
For a comprehensive approach to cardiac valve prostheses and cardiovascular implants, consider these related standards:
- EN ISO 5840-1: General requirements for heart valve substitutes
- EN ISO 5840-2: Requirements for surgically implanted heart valve substitutes
- ISO 14155: Clinical investigation of medical devices for human subjects - Good clinical practice
These standards, together with SIST EN ISO 5840-3:2021/A1:2025, help establish a rigorous framework for the design, testing, and clinical use of heart valve substitutes, supporting patient safety and fostering innovation in cardiac care.
Ensure that all device development and evaluation processes are aligned with the latest amendments and harmonized standards to meet global best practices and regulatory requirements in the cardiovascular medical device industry.
